BerGenBio ASA: Invitation to second quarter and half year 2023 results webcast
Bergen, Norway, 16 August 2023 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2023 on Wednesday 23 August 2023. The briefing will take place at the Conference “Vestland på Børs” at 10:45 am CEST where BerGenBio's senior management team will provide a business update. The presentation will webcast live, a link will be available at www.bergenbio.com in the Investors/Financial Reports section